M. Tardugno

Noncanonical type 2B von Willebrand disease associated with mutations in the VWF D'D3 and D4 domains.

B. Giusti, M. Papi, F. Bernardi, 2020, Blood advances.

THE MAIN PLAYERS OF THE GAME: VON WILLEBRAND FACTOR AND ADAMTS-13 Vascular rupture is rapidly counteracted by adhesion

A. Ferretti, Monica Sacco, S. Lancellotti, 2022 .

ADAMTS-13/von Willebrand factor ratio: A prognostic biomarker for portavein thrombosis in compensated cirrhosis. A prospective observational study.

F. Ponziani, L. Riccardi, M. Zocco, 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

The Von Willebrand factor-ADAMTS-13 axis: a two-faced Janus in bleeding and thrombosis

R. De Cristofaro, A. Ferretti, S. Lancellotti, 2022, Bleeding, Thrombosis, and Vascular Biology.

The p.P1127S pathogenic variant lowers von Willebrand factor levels through higher affinity for the macrophagic scavenger receptor LRP1: Clinical phenotype and pathogenic mechanisms

B. Giusti, M. Pinotti, A. Branchini, 2022, Journal of thrombosis and haemostasis : JTH.

Low ADAMTS-13/VWF ratio and altered gut–liver axis predict complications of advanced chronic liver disease: a pilot study

A. Gasbarrini, F. Ponziani, F. Santopaolo, 2022, Gastroenterology report.

Immune and Hereditary Thrombotic Thrombocytopenic Purpura: Can ADAMTS13 Deficiency Alone Explain the Different Clinical Phenotypes?

R. De Cristofaro, A. Ferretti, S. Lancellotti, 2023, Journal of clinical medicine.

Measurement of extended half-life recombinant FVIII molecules: In vitro and ex vivo evidence of relevant assay discrepancies

R. De Cristofaro, M. Mancuso, S. Lancellotti, 2023, Research and Practice in Thrombosis and Haemostasis.